Rain Therapeutics Q3 EPS $(0.68), Inline

Rain Therapeutics (NASDAQ:RAIN) reported quarterly losses of $(0.68) per share which met the analyst consensus estimate. This is a 2.86 percent increase over losses of $(0.70) per share from the same period last year.

Rain Therapeutics (NASDAQ:RAIN) reported quarterly losses of $(0.68) per share which met the analyst consensus estimate. This is a 2.86 percent increase over losses of $(0.70) per share from the same period last year.

Total
0
Shares
Related Posts
Read More

Toast Stock Pops After Hours On Q4 Performance – Here’s Why

Toast reported quarterly losses of 7 cents per share which beat the analyst consensus estimate of losses of 11 cents per share by 36.36%. The company reported quarterly sales of $1.04 billion which beat the analyst consensus estimate of $1.02 billion by 1.91% and represents a 34.72% increase over sales of $769 million from the same period last year.

TOST